Campbell & Co Investment Adviser’s Amedisys AMED Stock Holding History

Campbell & Co Investment Adviser’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,357	Closed	-$982K	–	863
2023 Q1	$982K	Buy	13,357 +9,707	+266%	+$840K	0.18%	166
2022 Q4	$305K	Buy	+3,650	New	+$329K	0.07%	547
2022 Q2	–	Sell	-3,108	Closed	-$535K	–	670
2022 Q1	$535K	Buy	+3,108	New	+$464K	0.14%	250
2021 Q4	–	Sell	-5,450	Closed	-$813K	–	608
2021 Q3	$813K	Buy	+5,450	New	+$1.13M	0.26%	106
2018 Q4	–	Sell	-3,300	Closed	-$412K	–	323
2018 Q3	$412K	Buy	+3,300	New	+$364K	0.28%	119
2018 Q1	–	Sell	-5,615	Closed	-$296K	–	351
2017 Q4	$296K	Buy	+5,615	New	+$296K	0.22%	190
2015 Q2	–	Sell	-35,077	Closed	-$939K	–	148
2015 Q1	$939K	Buy	+35,077	New	+$990K	0.59%	58

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Campbell & Co Investment Adviser's AMED Position: Q2 2023 in Review

Campbell & Co Investment Adviser sold out of Amedisys (AMED) in Q2 2023, closing a stake of 13,357 shares — an estimated $982K sold.

Campbell & Co Investment Adviser first reported a position in AMED in Q1 2015 and held it in 7 quarters. The position peaked at $982K in Q1 2023. 301 funds tracked by Wall St. Rank hold AMED as of Q2 2023.

Campbell & Co Investment Adviser reported no remaining Amedisys position as of Q2 2023 after selling out during the quarter.
Campbell & Co Investment Adviser sold 13,357 Amedisys shares in Q2 2023, an estimated $982K.
Campbell & Co Investment Adviser first reported a position in Amedisys in Q1 2015 and held it in 7 quarters.
Campbell & Co Investment Adviser's Amedisys position peaked at $982K in Q1 2023.
301 funds tracked by Wall St. Rank held Amedisys as of Q2 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2023, filed 11 Aug 2023.